Cargando…

An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19

Detalles Bibliográficos
Autores principales:	Homolak, Jan, Kodvanj, Ivan, Trkulja, Vladimir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892720/ https://www.ncbi.nlm.nih.gov/pubmed/33606199 http://dx.doi.org/10.1007/s40261-021-01007-8

Ejemplares similares

Publishing of COVID-19 preprints in peer-reviewed journals, preprinting trends, public discussion and quality issues
por: Kodvanj, Ivan, et al.
Publicado: (2022)

Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study
por: Trkulja, Vladimir, et al.
Publicado: (2023)

COVID-19 Mortality: The Culprit May Not Be Proton Pump Inhibitors
por: Duan, Zhihui, et al.
Publicado: (2022)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

Increased Proton Pump Inhibitors−Induced Mortality Risk in Hemodialysis Patients
por: Sertorio, Jonas T., et al.
Publicado: (2018)

Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients
por: Zirk-Sadowski, Jan, et al.
Publicado: (2017)

Widely available lysosome targeting agents should be considered as potential therapy for COVID-19
por: Homolak, J., et al.
Publicado: (2020)

Proton-pump inhibitors should be strictly prescribed in clinic
por: Yang, Xuesong, et al.
Publicado: (2022)

Deprescribing in older people: helpful tools and proton pump inhibitors
Publicado: (2020)

Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing
por: Trkulja, Vladimir
Publicado: (2021)

The costly case of proton-pump inhibitors: a single-center experience
por: Suresh Kumar, Vishnu Charan, et al.
Publicado: (2020)

There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
por: Trkulja, Vladimir
Publicado: (2022)

Preliminary analysis of COVID-19 academic information patterns: a call for open science in the times of closed borders
por: Homolak, J., et al.
Publicado: (2020)

Esomeprazole-Induced Chest Pain: A Case of an Unexpected Serious Adverse Reaction to a Proton Pump Inhibitor
por: Radas, Melanija Ražov, et al.
Publicado: (2020)

The Necessity of Validated Questionnaires: Determining Accurate Responses to Proton Pump Inhibitor Use
por: Jung, Kee Wook
Publicado: (2012)

High or Nonhigh Doses of Proton Pump Inhibitors for Patients with Peptic Ulcer Bleeding?
por: Hsieh, Yu-Hsi, et al.
Publicado: (2013)

Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease
por: Tariq, Muhammad Ali, et al.
Publicado: (2022)

Non-peer-reviewed data, effect measures, and meta-regression analysis on proton pump inhibitor use and COVID-19
por: Wu, Dan-Na, et al.
Publicado: (2022)

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

Meta-analysis associates proton pump inhibitor use with higher pneumonia risk in cirrhotic patients: mining for “diamonds” in the coal
por: Tziatzios, Georgios, et al.
Publicado: (2020)

Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011)

Does Helicobacter pylori eradication or proton pump inhibitor use benefit gastroesophageal reflux disease?
por: Sakin, Yusuf Serdar, et al.
Publicado: (2015)

Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis
por: Savarino, Edoardo, et al.
Publicado: (2016)

Subacute cutaneous lupus erythematosus due to proton pump inhibitor intake: case report and literature review
por: Reich, Adam, et al.
Publicado: (2012)

Unintended effects of proton pump inhibitors (PPIs) in patients with glioblastoma (GBM): A double-edged sword
por: Castro, Michael P
Publicado: (2022)

Reduced gastric acidity, proton pump inhibitors and increased severity of COVID-19 infections
por: Price, Elizabeth, et al.
Publicado: (2021)

Proton pump inhibitors increase risk of COVID-19
Publicado: (2020)

Do Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Really Have No Effect on the Gastric Emptying Rate?
por: Tomita, Toshihiko, et al.
Publicado: (2011)

Is hypomagnesemia associated with using proton pump inhibitors?
por: Yi, Joo-Hark, et al.
Publicado: (2016)

Rutin exerts antiulcer effect by inhibiting the gastric proton pump
por: Dubey, Shagun, et al.
Publicado: (2013)

por: Trkulja, Vladimir, et al.
Publicado: (2012)

Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?
por: Charpiat, Bruno, et al.
Publicado: (2020)

Do Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Really Have No Effect on the Gastric Emptying Rate?: Author's Reply
por: Nonaka, Takashi, et al.
Publicado: (2011)

Delirium in the geriatric unit: proton-pump inhibitors and other risk factors
por: Otremba, Iwona, et al.
Publicado: (2016)

Efficacy of Additives to Morphine Pumps in Post-Operative Pain Control of Addicted Patients
por: Bakshi, Sumitra G.
Publicado: (2011)

Proton pump inhibitors in the COVID-19 pandemic()
por: Sebastián Domingo, Juan J.
Publicado: (2021)

Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers
por: de Vries, F., et al.
Publicado: (2010)

Anti-infective properties of proton pump inhibitors: perspectives
por: da Rosa, Taciéli Fagundes, et al.
Publicado: (2021)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Exploration of Proton Pump Inhibitors Use During Pregnancy and Preeclampsia
por: Choi, Ahhyung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d2d6puk49in4shgfd7bsubogat